DNMT1 and myelodysplastic syndrome: MiR-185 and miR-152, act by suppressing DNMT1 activity in hepatocellular carcinoma cells [99] and prostate cancer respectively [100], promoting PTEN expression, also shown to be associated with HMA resistance in MDS [79].